Us2.v2 vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Us2.v2

by Eko.ai Pte. Ltd d/b/a Us2.ai

EchoNext

by Pathway Labs

AI Verdict

Both Us2.v2 and EchoNext are FDA-cleared AI tools focused on cardiac disease detection and clinical decision support within cardiology. Us2.v2 specializes in automating echocardiogram interpretation and reporting, offering comprehensive analysis of cardiac structures and function. In contrast, EchoNext analyzes standard ECGs to identify hidden structural heart disease, providing a different diagnostic approach for similar conditions.

Choose Us2.v2 if…

Choose Us2.v2 if your institution performs a high volume of echocardiograms and seeks to significantly reduce reporting time and increase daily scan throughput. This AI-powered tool automates the entire echocardiogram interpretation process, providing a complete structured report with measurements and disease detection (e.g., cardiac amyloidosis, heart failure, valvular disease) from any ultrasound manufacturer's images in seconds. It is ideal for streamlining workflow in echo labs, supporting clinical trials, and enabling efficient longitudinal follow-up.

View Us2.v2 →

Choose EchoNext if…

Choose EchoNext if you need a non-invasive, cost-effective screening tool to detect hidden structural heart disease from standard ECGs, especially in primary care or community settings where access to echocardiography is limited. This AI tool analyzes ECGs to identify risks for conditions like heart failure, valve disease, and pulmonary hypertension, helping to flag patients who require further cardiac ultrasound evaluation. It is well-suited for broad access and early detection of heart disease before symptoms present.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Us2.v2	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud, On-premise	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Us2.v2

Us2.v2 emphasizes 100% AI automation, eliminating manual frame selection and annotation, and delivers a complete structured echo report with zero clicks, significantly streamlining the workflow. It also offers transparent visual overlays and editable outputs, giving clinicians control. EchoNext, while providing AI-powered analysis, does not detail the same level of automation or user interaction features in its description.

Clinical Value

Us2.v2

Us2.v2 offers a comprehensive structured echo report with 45 automated parameters, including strain analysis, and detects a wider range of conditions directly from echocardiograms, such as cardiac amyloidosis, aortic stenosis, and various valvular diseases. EchoNext focuses on detecting hidden structural heart disease from ECGs, acting as a screening tool to identify patients who need a follow-up echocardiogram. While both are FDA-cleared and clinically validated, Us2.v2 provides a more definitive and comprehensive diagnostic output for echocardiography.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, offering clarity and different options for various organizational sizes. Us2.v2 requires contacting sales for custom pricing, which lacks transparency for initial evaluation. While Us2.v2 highlights efficiency gains like reducing reporting time by up to 70%, EchoNext's clear pricing structure offers more immediate value insight for potential buyers.

Enterprise Readiness

Us2.v2

Us2.v2 offers both cloud and on-premise deployment options, integrates seamlessly with existing PACS, CVIS, or EMR systems (HL7 and DICOM SR supported), and is compatible with any ultrasound manufacturer. This demonstrates a robust and flexible approach to enterprise integration. EchoNext is available through the OpenEvidence clinical decision support platform, which is a specific integration rather than broad deployment options.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. Us2.v2's 100% AI automation for comprehensive echocardiogram interpretation, including advanced parameters like strain analysis and vendor-neutral compatibility, is highly innovative. EchoNext's ability to detect hidden structural heart disease from standard ECGs, a traditionally limited diagnostic tool for such conditions, is also a groundbreaking advancement in early screening.

Support & Docs

Us2.v2

Us2.v2 provides a detailed user guide and emphasizes explainable AI with transparent visual overlays and editable outputs, suggesting comprehensive documentation and user control. It also highlights over 150 peer-reviewed studies validating its technology, indicating strong scientific backing and resources. While EchoNext has been validated in studies, specific details on user support and documentation are not as readily available in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Us2.v2	EchoNext
Name	Us2.v2	EchoNext
Company	Eko.ai Pte. Ltd d/b/a Us2.ai	Pathway Labs
Description	FDA-cleared, AI-powered tool that automates echocardiogram interpretation, delivering a complete structured echo report with measurements, disease detection, and clinical findings, making heart risk detection more accurate, consistent, and accessible worldwide.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Primary Input	Echocardiograms	Standard 12-lead ECGs
Key Detections	Cardiac amyloidosis, aortic stenosis, heart failure, pulmonary hypertension, valvular disease	Hidden structural heart disease, heart failure, valve disease, pulmonary hypertension indicators

Videos

Demos, reviews, and walkthroughs featuring Us2.v2 and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Us2.v2 is designed for seamless integration with existing PACS, CVIS, or EMR systems, supporting HL7 and DICOM SR. It connects to ultrasound devices and PACS, processing echocardiograms in real-time and delivering standardized reports directly into the cardiology PACS or reporting system. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by many physicians, allowing its screening output to be accessed within existing workflows without requiring a separate system.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

Us2.v2 automates echocardiogram interpretation, with segmentations of the left ventricle and left atrium showing accuracy between 91% and 99%. It has demonstrated good to excellent agreement with expert clinicians across 10 echocardiographic parameters and correctly identified 100% of pulmonary hypertension cases and all severe aortic stenosis cases in a prospective study. EchoNext, an AI-powered ECG model, achieved an AUROC of 85.2% and AUPRC of 78.5% in detecting structural heart disease in internal tests, and 78-80% in external validation. In studies, EchoNext alone achieved 77% accuracy in identifying structural heart disease from ECGs, outperforming cardiologists who achieved 64% accuracy.

Which cardiac specialties are these tools best suited for?

Us2.v2 is specifically designed for cardiology, automating echocardiogram interpretation and reporting for a wide array of heart-related conditions like heart failure, pulmonary hypertension, cardiac amyloidosis, and valvular disease. EchoNext is suitable for cardiology, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

What is the typical time-to-value for implementing these tools?

Us2.v2 can be deployed from kickoff to go-live in approximately one month, including scoping, installation, validation, and go-live phases. It aims to reduce overall echocardiography time, with studies showing a 70% reduction in analysis and reporting time, and can analyze a complete echo in 2-3 minutes. EchoNext's integration with the OpenEvidence platform aims to make the breakthrough in heart disease detection available everywhere care happens quickly, suggesting a rapid time-to-value once integrated into existing physician workflows.

What audit trail features are available to ensure transparency and accountability?

Us2.v2 offers explainable AI output, allowing users to evaluate all automated annotations and measurements, and provides transparent visual overlays and editable outputs in its reports. The reports are interactive and editable, allowing operators to update values which automatically updates the report. EchoNext's outputs are integrated into the OpenEvidence platform, which would likely have its own audit trail capabilities for clinical decision support, though specific EchoNext audit features are not detailed.

How do these tools support multi-site rollouts?

Us2.v2 offers both cloud and on-premise deployment options, making it adaptable for multi-site rollouts and compatible with various infrastructure setups. It is vendor-agnostic and can ingest DICOM images from any ultrasound manufacturer, facilitating consistent implementation across different equipment. EchoNext is designed for broad access, from major hospitals to community practices, and its partnership with OpenEvidence aims to get the tool into real workflows across health systems at a national scale.